AC Immune (ACIU) vs Entrada Therapeutics, Inc. (TRDA)
AC Immune and Entrada Therapeutics, Inc. are both Biotechnology companies. AC Immune and Entrada Therapeutics, Inc. are of similar size ($249.4M and $242.2M). AC Immune grew revenue faster over the last twelve months: −85.6% against −94.1%. AC Immune has the higher net margin (−1,783.7% vs −3,537.7%) and the higher return on invested capital (0.00% vs −1,060.2%). Across the 15 metrics below, AC Immune leads on 12 and Entrada Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | ACIU | TRDA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (1,745.75%) | (3,767.07%) | 0.00% |
| Net margin | (1,783.66%) | (3,537.73%) | 0.00% |
| Free cash flow margin | 0.00% | (2,867.07%) | 0.00% |
| Return on equity | 0.00% | (54.09%) | (57.72%) |
| Return on assets | 0.00% | (44.35%) | (49.22%) |
| Return on invested capital | 0.00% | (1,060.24%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack